Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580940 · ClinicalTrials.gov registry record
SpyGlass™ Discover Percutaneous
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 50
- Enrollment target
NCT04580940: Completed study, sponsored by Boston Scientific Corporation.
NCT04580940 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04580940 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
To document the clinical utility of percutaneous cholangiopancreatoscopy using a thin, disposable, flexible endoscope for evaluation and treatment of complex pancreaticobiliary disease in a prospective, multi-center case series
Primary Outcome
Physicians will report achieving clinical success by recording the completed procedures compared to procedures planned by 30 days (+/- 3 days) after index PTCS.
Interventions
- DEVICE SpyGlass™ Discover Digital System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2023-01-14 |
What the finished NCT04580940 record still lists
NCT04580940 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SpyGlass™ Discover Digital System is the first listed.
NCT04580940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04580940 about?
NCT04580940 is a clinical study titled "SpyGlass™ Discover Percutaneous". To document the clinical utility of percutaneous cholangiopancreatoscopy using a thin, disposable, flexible endoscope for evaluation and treatment of complex pancreaticobiliary disease in a prospective, multi-center case series
What is the current status of trial NCT04580940?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2021-07-27. Estimated completion is 2023-01-14.
What interventions are being tested in trial NCT04580940?
The interventions under investigation include: SpyGlass™ Discover Digital System (DEVICE).
Who is sponsoring clinical trial NCT04580940?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI